Trends in phase 1 oncology drug development in East-Asia and Australia

North America and Europe have been the traditional strongholds for conducting early phase clinical trials in oncology. However, the under-representation of Asians in cancer trials conducted especially in the United States (US) implies that the clinical data generated may not be generalizable to Asian patients from the rest of the world (1,2).